Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12070134 | 1.00 | EGFR (0.52) | EGFRHTTHSD17B10JAK2 | |
| SCHEMBL27739879 | 1.00 | EGFR (0.52) | EGFRHTTHSD17B10JAK2 | |
| SCHEMBL28775841 | 1.00 | EGFR (0.52) | EGFRHTTHSD17B10JAK2 | |
| SCHEMBL19172524 | 0.85 | EGFR (0.44) | EGFR | |
| SCHEMBL5561358 | 0.85 | CYP1A2 (0.49) | EGFRHSD17B10 | |
| SCHEMBL12364089 | 0.83 | EGFR (0.42) | EGFR | |
| SCHEMBL6601659 | 0.83 | EGFR (0.48) | EGFRHTTHSD17B10JAK2 | |
| SCHEMBL13298503 | 0.83 | MTNR1A (0.41) | EGFR | |
| SCHEMBL24445978 | 0.83 | KDM4E (0.43) | EGFRHTTHSD17B10 | |
| SCHEMBL3958089 | 0.81 | EGFR (0.47) | EGFRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4654966-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY AND DISEASES ASSOCIATED WITH FAT CELL ENLARGEMENT | MELLICELL, INC. (US) | 2025-12-03 | — | — | EP | disclosed |
| CN-114555585-B | HPK1 inhibitors and uses thereof | 锐格药业公司 | 2025-02-11 | — | — | CN | disclosed |
| WO-2024159211-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY AND DISEASES ASSOCIATED WITH FAT CELL ENLARGEMENT | MELLICELL, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| EP-3939981-B1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LIFEARC (GB) | 2024-04-03 | — | — | EP | disclosed |
| WO-2023134608-A1 | FUSED RING COMPOUNDS SERVING AS HPK1 INHIBITORS | 微境生物医药科技(上海)有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
| CN-108495855-B | Fused thiazolopyrimidine derivatives as MNK inhibitors | 生命弧度公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-114555585-A | HPK1 inhibitors and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2014102588-A2 | INDOLE AND INDOLINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2014-07-03 | — | — | WO | disclosed |
| US-8586550-B2 | Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2013-11-19 | — | — | US | disclosed |
| US-8586550-B2 | Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2013-11-19 | — | — | US | disclosed |
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | GREEN CROSS CORPORATION (KR) | 2013-04-11 | — | — | US | disclosed |
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | GREEN CROSS CORPORATION (KR) | 2013-04-11 | — | — | US | disclosed |
| WO-2011159067-A2 | THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159067-A2 | THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2011-12-22 | — | — | WO | disclosed |
| CN-101243075-A | Novel 2,3-dihydroindole compounds | LUNDBECK & CO AS H (DK) | 2008-08-13 | — | — | CN | disclosed |
| EP-1480641-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074051-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY LLC (GB) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | SLC5A2, SLC5A1, SLC10A2 | EGFR 1715/4885HTT 2195/4885HSD17B10 503/4885 |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | EGFR 1203/4885HTT 4056/4885HSD17B10 644/4885 |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | HIPK1, SIK1, PGK1 | EGFR 2594/4885HTT 2630/4885HSD17B10 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.